Tarsier® Pharma is a leading brand in the field of autoimmune and inflammatory ocular diseases. They are a late clinical-stage company dedicated to revolutionizing the treatment of these debilitating conditions. Their breakthrough therapeutic approach involves the use of the Dazdotuftide (TRS) Platform Technology, a bio-inspired immunomodulator.

This innovative technology is designed to effectively treat various inflammatory ocular diseases, including uveitis, glaucoma, and macular degeneration. Tarsier® Pharma's products are available in two forms: eye drops and intravitreal injections. By using this new immunomodulatory approach, they aim to disrupt the current treatment methods and provide better and safer solutions for patients around the world.

With a team of experienced professionals and strategic investments in ophthalmology, Tarsier® Pharma is at the forefront of developing advanced treatments for ocular inflammatory diseases. They prioritize patient safety and efficacy throughout their clinical trials and aim to bring relief to millions of individuals suffering from these conditions. Join Tarsier® Pharma in their mission to transform the landscape of ocular inflammatory diseases and safeguard precious vision